Full-Time

Vice President US Market Access Lead

Specialty Care

Updated on 9/12/2026

Deadline 9/26/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$300.1k - $500.1k/yr

+ 30% bonus target + Share-based long-term incentive program

No H1B Sponsorship

New York, NY, USA

Hybrid

Requires working from New York headquarters 2 to 3 days per week. Domestic travel up to approximately 25%.

Bachelor's, MBA

Category
Growth & Marketing (1)
Required Skills
Branding/Brand Strategy

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree.
  • At least 15 years of experience in the healthcare sector, including demonstrated success in market access, payer strategy, or brand-level access roles.
  • Deep understanding of the United States healthcare environment, including payer dynamics, formulary mechanics, gross-to-net economics, and distinct access requirements across brand lifecycle stages.
  • Demonstrated experience developing and executing integrated brand market access plans, including payer marketing, pricing strategy, and contracting strategy.
  • A proven track record of operating at a senior leadership level, leading a team, owning outcomes, and serving as an enterprise partner to senior business-unit leadership.
  • Ability to integrate access marketing, contracting, account management, and patient services capabilities and present a unified access perspective to the business unit.
  • Demonstrated business and financial acumen, including understanding brand profit-and-loss dynamics and translating them into access investment and gross-to-net trade-off decisions.
  • Strong influence and negotiation skills, with the ability to build trust and drive alignment with senior stakeholders across business-unit and USMAPPS functions.
  • Strong communication skills and the ability to represent USMAPPS credibly with business-unit presidents and franchise leads at senior levels.
  • Previous supervisory and people-management experience, including developing and motivating others and leading through change.
  • Demonstrated agility with organizational change and the ability to lead through ambiguity while delivering on business objectives.
  • Candidates must be authorized to be employed in the United States by any employer.
  • Permanent work authorization in the United States is required.
Responsibilities
  • Develop and maintain a fully integrated brand market access plan for all Specialty Care brands covering payer marketing, contracting strategy, and pricing strategy.
  • Translate portfolio-level access priorities into brand-specific execution plans aligned with enterprise gross-to-net objectives.
  • Define payer value propositions, messaging, and positioning for Specialty Care brands with access marketing resources.
  • Ensure brand-level pricing and contracting strategies optimize net trade sales and gross-to-net outcomes across payer, group purchasing organization, and channel.
  • Define and monitor access performance metrics at brand and portfolio levels, including access quality, access speed, gross-to-net performance, and launch readiness.
  • Reassess and reallocate brand-level resources based on lifecycle stage, launch timing, and business priority.
  • Adjust access plans in response to IRA drug-pricing dynamics, 340B evolution, pharmacy benefit manager-payer consolidation, and formulary changes.
  • Serve as the single point of communication and accountability between USMAPPS and the Specialty Care business-unit president and franchise leads for access, contracting strategy, and payer marketing needs.
  • Serve on the Specialty Care business-unit leadership team as the primary USMAPPS advisor to franchise leads.
  • Represent Specialty Care business-unit access needs in USMAPPS leadership and escalate resource gaps, strategic misalignment, and unresolved cross-functional tensions.
  • Partner with franchise leads to understand brand profit-and-loss objectives and translate them into access, contracting, and payer-marketing priorities.
  • Drive enterprise-level decision-making regarding trade-offs between revenue maximization and gross-to-net discipline.
  • Own the access chapter of strategic brand plans for Specialty Care pipeline assets.
  • Identify and close access-readiness gaps, including payer coverage, specialty-pharmacy pull-through, reimbursement pathways, and formulary positioning.
  • Establish and track launch-access key performance indicators with Strategic Account Management, brand teams, and customer-engagement teams.
  • Define three-year market access plans for pipeline assets and incorporate gross-to-net inputs into long-range financial planning.
  • Coordinate USMAPPS functional support across access marketing, contracting strategy, pharmacy engagement, Strategic Account Management, and Patient Services before engaging the Specialty Care business unit.
  • Maintain ownership accountability for brand-level access pull-through by coordinating execution with Strategic Account Management and flagging gaps to business-unit leadership.
  • Identify and resolve gaps or misalignment across functional teams before escalation to functional leaders or the business-unit president.
  • Establish ways of working that prevent fragmentation, redundancy, or misaligned seniority across supporting functions.
  • Serve as a limited interface for Market Access Operations on contract-execution issues requiring brand-level context.
  • Lead and develop a team aligned to Specialty Care brands and franchise clusters while maintaining accountability for brand-level access outcomes and deliverables.
  • Coach and develop team members to operate as strategic owners with accountability for outputs.
  • Identify strong internal candidates for team roles and pursue external sourcing when internal talent is unavailable.
  • Create career-development pathways within the Specialty Care access vertical.
  • Coach, develop, and engage direct reports and participate in recruitment and selection of staff.
  • Participate as a core member of the USMAPPS Leadership Team and contribute to enterprise strategy and cross-functional alignment.
  • Model Pfizer values and leader behaviors.
Desired Qualifications
  • An MBA or advanced degree in a healthcare-related or business field.
  • Prior experience in a brand-facing market access role or as a member of a business-unit leadership team.
  • Experience managing across multiple brands or franchise clusters simultaneously.
  • Familiarity with IRA implications, 340B dynamics, and other policy-driven access considerations relevant to a large, diversified pharmaceutical portfolio.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.